Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical Activated Collagen Adjuvant powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. It also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers; and PULSAR II Advanced Wound Irrigation System, a portable and no touch hydro-mechanical debridement system that removes bacteria and necrotic tissue without disrupting healthy tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
IPO Year:
Exchange: NASDAQ
Website: sanaramedtech.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/26/2025 | $50.00 → $51.00 | Buy | H.C. Wainwright |
| 12/23/2024 | $50.00 | Buy | H.C. Wainwright |
| 5/20/2022 | $45.00 → $40.00 | Overweight | Cantor Fitzgerald |
| 6/30/2021 | $45.00 | Overweight | Cantor Fitzgerald |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Sanara MedTech Inc. (0000714256) (Issuer)
3 - Sanara MedTech Inc. (0000714256) (Issuer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
8-K - Sanara MedTech Inc. (0000714256) (Filer)
10-Q - Sanara MedTech Inc. (0000714256) (Filer)
8-K - Sanara MedTech Inc. (0000714256) (Filer)
8-K - Sanara MedTech Inc. (0000714256) (Filer)
8-K - Sanara MedTech Inc. (0000714256) (Filer)
10-Q - Sanara MedTech Inc. (0000714256) (Filer)
8-K - Sanara MedTech Inc. (0000714256) (Filer)
8-K - Sanara MedTech Inc. (0000714256) (Filer)
8-K - Sanara MedTech Inc. (0000714256) (Filer)
10-Q - Sanara MedTech Inc. (0000714256) (Filer)
Live finance-specific insights
Net Revenue Increased 22% Year-Over-Year in Q3; Increased 25% Year-Over-Year in First Nine Months of 2025 FORT WORTH, TX, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary (2) ●Net revenue increased 22% to $26.3 million, compared to $21.7 million in the third quarter of 2024. ●Net income from continuing operations of $
FORT WORTH, TX, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its third quarter 2025 financial results on Wednesday, November 12, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on November 12, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended September 30, 2025 and hold a question and answer session at the end of the call. Th
Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary ●Net revenue increased 28% to
FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial results on Wednesday, August 13, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on August 13, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended June 30, 2025 and hold a question and answer session at the end of the call. The toll-f
Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary ●Net revenue increased 26% to $23.4 million, compared to $18.5 million in the first quarter of 2024. ●Net loss of $3.5 million, compared to a net loss of $1.8 million in the first quar
FORT WORTH, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its first quarter 2025 financial results on Wednesday, May 14, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on May 14, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended March 31, 2025 and hold a question and answer session at the end of the call. The toll-fr
Q4 Net Revenue Increased 49% Year-Over-Year; 2024 Net Revenue Increased 33% Year-Over-Year FORT WORTH, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary ●Net revenue increased 49% to $26.3 million, compared to $17.7 million in the fourth quarter of 2023. ●Net loss of
FORT WORTH, TX, March 11, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its fourth quarter and full year 2024 financial results on Tuesday, March 25, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on March 25, 2025 at 8:00 a.m. Eastern Time to discuss the results for the quarter and full year ended December 31, 2024, and hold a question and answer session
FORT WORTH, TX, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its strategic, operational and financial results for the quarter ended September 30, 2024. "The third quarter of 2024 was Sanara's twelfth consecutive record net revenue quarter, which is a testament to the hard work and dedication of our entire organization," stated Ron Nixon, Sanar
FORT WORTH, TX, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced details for the release of its results for the quarter ended September 30, 2024. Sanara will issue its earnings release on Tuesday, November 12, 2024, and will host a conference call on Wednesday, November 13, 2024, at 9:00 a.m. Eastern Time. The toll-free number to call for t
Fastest customizable press release news feed in the world
Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic's granted patent in 2025 FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, together with Biomimetic Innovations Ltd ("BMI"), today provided an update on progress related to their strategic alliance. In addition, Sanara reaffirmed its plans to introduce OsStic™ Synthetic Injectable Structural Bio-Adhesive ("OsStic") to the U.S.
FORT WORTH, TX, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that management will participate in the Piper Sandler 37th Annual Healthcare Conference, which is being held at The Lotte New York Palace in New York, NY from December 2 – 4, 2025. Management will deliver a presentation to investors on Wednesday, December 3 at approximately 9:30 a.m. Eastern Time. The presentation materials for the conference will be posted to
Net Revenue Increased 22% Year-Over-Year in Q3; Increased 25% Year-Over-Year in First Nine Months of 2025 FORT WORTH, TX, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary (2) ●Net revenue increased 22% to $26.3 million, compared to $21.7 million in the third quarter of 2024. ●Net income from continuing operations of $
Completes Evaluation of Strategic Alternatives for Tissue Health Plus Segment FORT WORTH, TX, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that the Company completed its previously announced evaluation of strategic alternatives for Tissue Health Plus ("THP"). Following the completion of this evaluation, the Company initiated a strategic realignment of its business, discontinuing operations of THP to improve its operati
FORT WORTH, TX, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its third quarter 2025 financial results on Wednesday, November 12, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on November 12, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended September 30, 2025 and hold a question and answer session at the end of the call. Th
Seth Yon Appointed President, Chief Executive Officer and Director; Ron Nixon to Remain Executive Chairman FORT WORTH, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that Seth Yon, Sanara's President and Chief Commercial Officer, has been appointed to the position of President and Chief Executive Officer and will join the Board of Directors, effective September 15, 2025. Mr. Yon will succeed
FORT WORTH, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that management will present at the Cantor Global Healthcare Conference, which is being held at the New York Marriott Marquis in New York, NY from September 2 – 5, 2025. Management will participate in a fireside chat presentation session on Wednesday, September 3 at approximately 2:45 p.m. Eastern Time. The presentation materials for t
Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary ●Net revenue increased 28% to
FORT WORTH, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its second quarter 2025 financial results on Wednesday, August 13, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on August 13, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended June 30, 2025 and hold a question and answer session at the end of the call. The toll-f
Pilot program designed to provide real-world evidence in the use of Tissue Health Plus' technology platform FORT WORTH, TX, July 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced the recent launch, through its subsidiary, Tissue Health Plus, LLC ("THP"), of its wound care provider pilot program, a first of its kind, value-based wound care offering designed for payers and risk-bearing entities, as well as
This live feed shows all institutional transactions in real time.
SC 13G - Sanara MedTech Inc. (0000714256) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright reiterated coverage of Sanara MedTech with a rating of Buy and set a new price target of $51.00 from $50.00 previously
H.C. Wainwright initiated coverage of Smtek with a rating of Buy and set a new price target of $50.00
Cantor Fitzgerald resumed coverage of Smtek with a rating of Overweight and set a new price target of $40.00 from $45.00 previously
Cantor Fitzgerald initiated coverage of Sanara MedTech with a rating of Overweight and set a new price target of $45.00
Live Leadership Updates
Elizabeth Taylor Appointed Chief Financial Officer; Michael McNeil Appointed Chief Accounting Officer and Chief Administrative Officer FORT WORTH, TX, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the expansion of the Company's executive leadership team with new appointments. Elizabeth Taylor has been appointed to the position of Chief Financia
FORT WORTH, TX, April 05, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer. Zach Fleming, Sanara's Chief Executive Officer, stated, "Jake and Tyler are seasoned executives with a wealth of experience in the medical device and woun
FORT WORTH, TX, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Zachary ("Zach") B. Fleming has been appointed Chief Executive Officer effective January 1, 2022. Ron Nixon, Sanara's Executive Chairman, stated, "Zach is an outstanding leader who has been a driving force behind the development and execution of our surgical wound strategy. During his time as President of the Surgical Division, he has overseen double-digit year over year revenue growth of our business and steered the division through the ch
FORT WORTH, TX , Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that J. Michael ("Mike") Carmena will step down from the Company's Board of Directors (the "Board") and resign as the Company's Principal Executive Officer, effective December 31, 2021 and Eric Tanzberger has been appointed to the Company's Board effective January 1, 2022. Concurrently with his appointment to the Board, Mr. Tanzberger was appointed Chair of the Audit Committee. Ron Nixon, Sanara's Executive Chairman, stated, "Mike was a key leade
FORT WORTH, TX, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Roszell Mack III has been appointed to the Company's Board of Directors (the "Board"), effective January 1, 2022. Ron Nixon, Sanara's Executive Chairman, stated, "Rosz is a tremendous addition to Sanara's Board. He has an extensive background in finance, global markets, and scaling technology ventures. We believe his expertise in these areas will add a valuable perspective to our board as we continue to execute our comprehensive wound and ski
FORT WORTH, TX / ACCESSWIRE / December 23, 2020 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ:SMTI), a provider of wound and skin care products dedicated to improving patient outcomes, announced today that Sara Ortwein has been appointed to the Company's Board of Directors (the "Board"), effective December 18, 2020. Ron Nixon, Sanara's Executive Chairman, stated, "Sara is an excellent addition to our Board. She brings diversity of thought and Fortune 500 experience at the executive level as well as a strong background in science and engineering. We believe she will bring a valuable perspective to Sanara as we continue to expand and